The 76th ADLM Clinical Lab Expo & Convention (formerly AACC) was held from July 30 to August 1, 2024, at McCormick Place in Chicago, USA. The event brought together more than 900 exhibitors and over 70,000 clinical laboratory and healthcare professionals from around the world.
At this year's exhibition, Medconn, one of China's leading IVD companies, made a strong appearance with its flagship HbA1c testing solutions and other in vitro diagnostic products. Backed by strong product capabilities and continuous innovation, Medconn attracted significant attention and recognition from industry professionals and international customers. Interest from overseas markets surged, with a substantial increase in potential orders continuing even after the exhibition.
Event Highlights
With its flagship HbA1c solutions, Medconn once again brought its innovative products and technologies to the international stage. At ADLM 2024, Medconn presented a comprehensive portfolio of diagnostic solutions and engaged with customers and industry partners from around the world to exchange insights and explore opportunities for collaboration.
The exhibition also provided an important opportunity for Medconn to further expand its customer network across North and South America. Strong market interest and a significant increase in potential orders reflected growing international recognition of the Medconn brand, with customer inquiries continuing to rise after the event.
Product Showcase
At the exhibition, Medconn showcased its flagship HbA1c analyzers, including the MQ-8000, MQ-3000, and MQ-2000PT, attracting considerable attention from visitors. The Medconn booth welcomed a steady stream of professionals for product consultations and technical exchanges.
With more than a decade of experience in the field of diabetes diagnostics, Medconn has developed a comprehensive HbA1c product portfolio based on high-performance liquid chromatography (HPLC) with ion-exchange technology, a widely recognized reference method for HbA1c testing. Medconn's HbA1c solutions deliver fast and efficient testing with reliable and accurate results and have obtained both NGSP and IFCC certifications.
From large tertiary hospitals to clinics and community healthcare facilities, Medconn offers solutions tailored to the needs of different healthcare settings, supporting accurate diagnosis and more informed clinical decision-making.
Continuous innovation in both technology and service is also a key driver of Medconn's international growth. By continuously improving its products and solutions, Medconn is contributing new momentum to the development of the global IVD industry.
Although ADLM 2024 has come to an end, interest in Medconn's products continues to grow. The steady increase in post-show inquiries has further strengthened Medconn's confidence in its global expansion strategy.
Following the successful conclusion of the exhibition, Medconn will continue to accelerate its expansion into the international IVD market, focusing on the continuous innovation and advancement of integrated IVD solutions and the development of a global healthcare ecosystem. Medconn is committed to providing high-quality products and services to partners worldwide while working together with industry stakeholders to shape the future of in vitro diagnostics.
Looking Ahead
Looking to the future, Medconn will continue to uphold a customer-centric philosophy, driving continuous innovation in technology and services while consistently improving the quality of its products and solutions.
As demand for healthcare services continues to grow worldwide and technological advances accelerate, medical laboratories are evolving to meet changing market and clinical needs. Medconn will remain committed to its global expansion and international development strategy, guided by its mission of “Navigating Medicine with Diagnostics.”
By providing customized solutions for laboratories of different sizes and leveraging technological innovation to address evolving customer needs, Medconn aims to create greater value together with its global partners, contribute to continued industry progress, and bring new momentum to the development of the global in vitro diagnostics industry.
